Clinical Trial Update: NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS [Phase 1]

View source ↗

Summary

Nkarta's NKX101 is an intravenous allogeneic CAR-NK cell therapy being studied in adults with relapsed/refractory acute myeloid leukemia and myelodysplastic syn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• NKX101

Snippet

Sponsor: Nkarta, Inc. | Conditions: Relapsed/Refractory AML, AML, Adult | Phase 1 | Status: ACTIVE_NOT_RECRUITING